Senseonics reported a sharp increase in third-quarter revenue, driven mainly by U.S. demand for its Eversense 365 continuous glucose monitor, and raised its full-year revenue and gross-margin outlook. The company also described efforts to expand access to the device through a growing network of trained inserters and new insulin-pump compatibility, while continuing development of next-generation products.
Revenue growth and improved gross margin came alongside higher operating expenses and a wider net loss. Senseonics ended September with $126.6 million in cash, restricted cash and short-term investments.
Key details
- Revenue climbed 140% year over year to $19.6 million. U.S. revenue rose 160% to $16.8 million, while revenue outside the U.S. increased about 65% to $2.8 million. The company said record U.S. shipment volume and a roughly 90% increase in active prescribers contributed to domestic growth.
- Senseonics raised its 2026 revenue outlook to $68 million–$70 million, from $62 million–$66 million. The new range implies annual growth of 93%–98%. With U.S. sales growing faster than expected, the company now expects markets outside the U.S. to account for about 15% of full-year revenue.
- Gross margin improved to about 62%, from 43% a year earlier. Gross profit was $12.1 million, compared with $3.5 million in the third quarter of 2025. Senseonics also raised its full-year gross-margin outlook to more than 60%, from a prior range of 58%–61%.
- Expenses and losses increased. Research and development costs rose to $11.7 million from $7.8 million, reflecting clinical work on Gemini and development of Freedom. Selling, general and administrative expenses increased to $32.3 million from $15.3 million, reflecting the cost of the company’s U.S. and European commercial teams. Net loss widened to $32.7 million, or 50 cents per share, from $19.5 million, or 43 cents per share, a year earlier.
- Cash and debt: At September 30, Senseonics had $126.6 million in cash, cash equivalents, restricted cash and short-term investments. Debt under its Hercules Capital facility had a carrying value of about $56.2 million, with $55 million of principal outstanding—unchanged from the second quarter.
- The company is expanding its EON Care inserter network. It had more than 100 inserters, who performed over 40% of Eversense insertion procedures in the quarter. Senseonics raised its year-end target for the network to 120.
- A new pump partnership is planned to broaden Eversense compatibility. Senseonics plans to integrate Eversense 365 with Beta Bionics’ iLet Bionic Pancreas, with a commercial launch planned for the fourth quarter of 2026, subject to completion of integration work and applicable requirements. The company also cited its existing work with Sequel to connect Eversense 365 with the twiist automated insulin delivery system.
- Senseonics began the first-in-human study of Freedom, an investigational next-generation glucose monitor designed to communicate directly with a mobile device without an on-body component. The company said the system builds on sensor technology and clinical experience shared with Eversense 365 and Gemini.
What changes for investors: The higher outlook reflects the company’s stronger-than-expected sales momentum and improved gross margin. At the same time, the larger quarterly loss shows that commercial expansion and product development are carrying substantial costs. The Beta Bionics integration and the growing inserter network are part of Senseonics’ effort to widen patient access to Eversense.